American Association for Cancer Research
Browse
crc-23-0415-s12.pptx (5.57 MB)

Figure S9 from Epigenetic Priming by Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-cell Lymphoma

Download (5.57 MB)
figure
posted on 2024-06-06, 14:20 authored by George A. Ward, Zhiqiang Zhang, Simone Jueliger, Ilya S. Potapov, Matthew P. Davis, Adam R. Boxall, Jason Taylor, Harold Keer, Andrea Biondo, John F. Lyons, Martin Sims, Tomoko Smyth

Figure S9. Analysis of tumor and plasma samples from EL4-Parental and EL4-C8KO syngeneic model PD studies (Refers to Figure 6)

Funding

Astex Pharmaceuticals (Astex)

History

ARTICLE ABSTRACT

Programmed cell death mechanisms are important for the regulation of tumor development and progression. Evasion of and resistance to apoptosis are significant factors in tumorigenesis and drug resistance. Bypassing apoptotic pathways and eliciting another form of regulated cell death, namely necroptosis, an immunogenic cell death (ICD), may override apoptotic resistance. Here, we present the mechanistic rationale for combining tolinapant, an antagonist of the inhibitor of apoptosis proteins (IAP), with decitabine, a hypomethylating agent (HMA), in T-cell lymphoma (TCL). Tolinapant treatment alone of TCL cells in vitro and in syngeneic in vivo models demonstrated that ICD markers can be upregulated, and we have shown that epigenetic priming with decitabine further enhances this effect. The clinical relevance of ICD markers was confirmed by the direct measurement of plasma proteins from patients with peripheral TCL treated with tolinapant. We showed increased levels of necroptosis in TCL lines, along with the expression of cancer-specific antigens (such as cancer testis antigens) and increases in genes involved in IFN signaling induced by HMA treatment, together deliver a strong adaptive immune response to the tumor. These results highlight the potential of a decitabine and tolinapant combination for TCL and could lead to clinical evaluation. The IAP antagonist tolinapant can induce necroptosis, a key immune-activating event, in TCL. Combination with DNA hypomethylation enhances tolinapant sensitivity and primes resistant cells by re-expressing necrosome proteins. In addition, this combination leads to increases in genes involved in IFN signaling and neoantigen expression, providing further molecular rationale for this novel therapeutic option.